Fondaparinux sodium

Fondaparinux sodium is the first of a new class of direct-acting antithrombin agents. The anticoagulant activity of heparin depends on the binding of ATIII to a critical pentasaccharide sequence within the heparin molecule. This results in a change in the conformation of AITII. This leads to the inhibitory effect of ATIII on factor Xa, which activates the conversion of prothrombin to thrombin. Fondaparinux is a synthetic pentasaccharide identical to the ATIII-binding site of heparin. 

Donat p Duret JP Santoni A, et al. The pharmacokinetics of fondaparinux sodium in healthy volunteers, Clin Pharmacokinet 2002 41 Suppl 2 1-9,... 

Fondaparinux sodium, a selective inhibitor of coagulation factor Xa, is eUminated by the kidneys. In a randomized, crossover study in 24 healthy volunteers the pharmacokinetics and pharmacodynamics of digoxin 0.25 mg/day orally for 7 days were unaffected by fondaparinux sodium 10 mg/day subcutaneously for 7 days (260). 

In a randomized, crossover study in 24 healthy volunteers, the pharmacokinetics of fondaparinux sodium 10 mg/day subcutaneously for 7 days were unaffected by digoxin... 

Reverter JC. Fondaparinux sodium. Drugs Today (Bare) 2002 38(3) 185-94. 

Ollier C, Faaij RA, Santoni A, Duvauchelle T, van Haard PM, Schoemaker RC, Cohen AF, de Greef R, Burggraaf J. Absence of interaction of fondaparinux sodium with aspirin and piroxicam in healthy male volunteers. Clin Pharmacokinet 2002 41(Suppl 2) 31-7. 

Arixtra (Fondaparinux sodium). GlaxoSmithKline UK. UK Summary of product characteristics, April 2007. 

Lieu, C. Shi, J. Donat, F. Van Horn, R. Brian, W. Newton, J. Delbressine, L. Vos, R. Fondaparinux sodium is not metabolised in mammalian Uver fractions and does not inhibit cytochrome P450-mediated metabolism of concomitant drugs, Clin.Pharmacokinet., 2002, 4i(Suppl. 2), 19-26. 

---